uniQure N.V. (NASDAQ:QURE) Receives Average Recommendation of “Moderate Buy” from Analysts

uniQure N.V. (NASDAQ:QURE) has received a consensus recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $60.8182.

A number of equities research analysts have weighed in on the company. William Blair reiterated a “market perform” rating on shares of uniQure in a report on Tuesday, November 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of uniQure in a research report on Wednesday. Royal Bank Of Canada dropped their target price on shares of uniQure from $65.00 to $45.00 and set an “outperform” rating on the stock in a research report on Monday, November 3rd. Chardan Capital reissued a “buy” rating and set a $53.00 target price on shares of uniQure in a research note on Thursday, December 4th. Finally, Wells Fargo & Company decreased their price target on shares of uniQure from $80.00 to $60.00 and set an “overweight” rating for the company in a research note on Wednesday, November 12th.

uniQure Price Performance

QURE stock opened at $25.08 on Monday. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.23. The firm has a market cap of $1.56 billion, a price-to-earnings ratio of -5.71 and a beta of 0.68. The company’s fifty day simple moving average is $24.12 and its 200 day simple moving average is $28.02. uniQure has a 12-month low of $7.76 and a 12-month high of $71.50.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.53). The business had revenue of $3.70 million during the quarter, compared to the consensus estimate of $4.46 million. uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%. On average, analysts expect that uniQure will post -3.75 earnings per share for the current year.

Insider Transactions at uniQure

In related news, Director Robert Gut sold 25,613 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $24.62, for a total transaction of $630,592.06. Following the transaction, the director directly owned 32,342 shares of the company’s stock, valued at approximately $796,260.04. This represents a 44.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jack Kaye sold 6,390 shares of the stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $27.28, for a total value of $174,319.20. Following the completion of the transaction, the director owned 20,439 shares in the company, valued at approximately $557,575.92. The trade was a 23.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 102,247 shares of company stock valued at $2,839,298 over the last ninety days. 4.79% of the stock is currently owned by corporate insiders.

Institutional Trading of uniQure

A number of hedge funds and other institutional investors have recently bought and sold shares of QURE. Assetmark Inc. acquired a new position in uniQure during the fourth quarter worth $445,000. Aberdeen Group plc raised its holdings in shares of uniQure by 25.1% in the 4th quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock worth $88,030,000 after acquiring an additional 738,897 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its holdings in shares of uniQure by 31.2% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 67,739 shares of the biotechnology company’s stock worth $1,621,000 after acquiring an additional 16,126 shares during the last quarter. SG Americas Securities LLC lifted its position in uniQure by 508.1% in the 4th quarter. SG Americas Securities LLC now owns 64,326 shares of the biotechnology company’s stock valued at $1,539,000 after acquiring an additional 53,747 shares in the last quarter. Finally, Assenagon Asset Management S.A. acquired a new position in uniQure during the 4th quarter valued at about $14,524,000. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.